IntroductionNLP is an inflammatory, relatively rare disorder involving mainly the nail matrix, frequently having its onset in adulthood and generally involving one or more nails or toenails [1]. The management of NLP is not easy due to a high rate of failures after therapy and few therapeutic options, especially when the process reaches the stage of dorsal pterygium [1]. Janus kinase (JAK) inhibitors are potential therapeutic targets for inflammatory skin diseases. They have been demonstrated to suppress both type-1 and type-2 cytokines and decrease the immune response, leading to inflammation [2]. This paper reports a case of severe NLP showing a good response to the JAK inhibitor (Tofacitinib).

Successful Treatment of Refractory Bullous Pemphigoid with Omalizumab in a Liver Transplant Recipient: A Case Report

A document by Sima Shamshiri Khamene. Click on the document to view its contents.

IntroductionHydroxyurea (HU) is a potent myelosuppression drug reducing deoxyribonucleotide production (1) and treats chronic myelogenous leukemia (CML), polycythemia vera (PV), and essential thrombocytosis (ET) (2). HU has some side effects, including dermatologic side effects, especially during long-term treatment, the most common of which are nail changes, hyperpigmentation, atrophy of the skin, partial alopecia, subcutaneous tissue changes, scaling, hands and face erythema, and less common lower extremity ulceration (3-5).In the literature, some cases of HU-related cutaneous squamous cell carcinoma (SCC) are reported (6-8). Accordingly, we reviewed and summarized the literature on the relationship between HU and skin cancer.

Granular parakeratosis is an acquired keratinization disease. We describe the unusual presentation of granular parakeratosis. A 27-year-old healthy female presented with multiple erythematous and brown discoloration plaques on the dorsal aspect of her hands for eight months. Repeated washing, using detergents, and maceration of the skin could develop her lesion.

This study reports a patient developing TEN after the first dose of (BBIBP-CorV). He developed numerous purpuric and dusky patches with flaccid bullae and areas of epidermal detachment covered more than 30% of the body area within 6 days. After treatment with dexamethasone and cyclosporin, he recovered within 14 days.

We report a case of cutaneous lymphangioma secondary to breast cancer radiotherapy after mastectomy.